Genentech’s Tecentriq Moves Closer to Potential New Standard of Care in Early Colon Cancer Following FDA Priority Review Acceptance
Genentech, a member of the Roche Group, has announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental Biologics License Application (sBLA) seeking approval for adjuvant Tecentriq® (atezolizumab) and Tecentriq Hybreza® (atezolizumab and hyaluronidase-tqjs) in combination with chemotherapy for patients with stage III deficient DNA mismatch repair (dMMR) or microsatellite instability-high (MSI-H) colon cancer. The FDA has also granted the application Priority Review status, reflecting the potential significance of the therapy in addressing an important unmet medical need.
Under the Priority Review designation, the FDA is expected to complete its review and issue a regulatory decision by October 9, 2026. If approved, the treatment combination could become the first immunotherapy-based adjuvant regimen specifically indicated for patients with stage III dMMR/MSI-H colon cancer, potentially reshaping treatment approaches for a subset of patients at high risk of disease recurrence following surgery.
The application is supported by results from the landmark Phase III ATOMIC study, which demonstrated substantial improvements in disease-free survival when Tecentriq was added to standard chemotherapy. The findings have generated significant interest among oncologists and patient advocacy groups, as they point toward a new strategy for reducing recurrence risk in patients with biologically distinct forms of colon cancer.
A Potential Advancement in Early-Stage Colon Cancer Treatment
Colon cancer remains one of the most commonly diagnosed cancers worldwide and continues to be a leading cause of cancer-related mortality. Although advances in screening, surgery, and systemic therapies have improved outcomes over the years, recurrence remains a major challenge, particularly for patients diagnosed with stage III disease.
For many patients, surgery is the cornerstone of treatment. However, even after successful surgical removal of the tumor, microscopic cancer cells can remain in the body and eventually lead to recurrence. To reduce this risk, patients commonly receive adjuvant chemotherapy after surgery.
Despite these efforts, approximately one-third of patients with stage III colon cancer experience disease recurrence within five years. This reality has fueled the search for more effective postoperative treatment strategies capable of improving long-term outcomes.
The FDA’s acceptance of Genentech’s application represents an important milestone in that effort. By incorporating immunotherapy into the adjuvant treatment setting, researchers hope to improve the body’s ability to recognize and eliminate residual cancer cells before they can trigger relapse.
Understanding dMMR and MSI-H Colon Cancer
The proposed indication focuses on patients whose tumors are characterized by deficient DNA mismatch repair (dMMR) or high microsatellite instability (MSI-H).
These biomarkers identify a distinct subtype of colon cancer that differs biologically from many other colorectal tumors. Deficient mismatch repair occurs when cellular mechanisms responsible for correcting DNA replication errors fail to function properly. As a result, mutations accumulate throughout the tumor genome.
Microsatellite instability-high tumors are closely associated with this process and typically exhibit elevated mutation rates. Because these cancers generate numerous abnormal proteins, they may be more visible to the immune system and therefore more responsive to immunotherapy.
Approximately 15% of colon cancer patients have dMMR or MSI-H tumors. While these patients often demonstrate unique clinical characteristics, they have historically been treated with many of the same approaches used for broader colon cancer populations.
The ATOMIC study was designed to determine whether introducing immunotherapy earlier in the treatment journey could provide additional benefits for this specific patient group.
ATOMIC Trial Delivers Promising Results
The FDA filing is based on data from the Phase III ATOMIC trial, a large international study evaluating the addition of Tecentriq to standard chemotherapy following surgery.
The trial investigated Tecentriq combined with FOLFOX6 chemotherapy, a widely used treatment regimen consisting of fluorouracil, leucovorin, and oxaliplatin. Researchers compared this combination against FOLFOX6 chemotherapy alone in patients with stage III dMMR colon cancer.
Results from the study demonstrated a significant reduction in the risk of disease recurrence or death among patients receiving the immunotherapy combination.
According to the data, adding Tecentriq to chemotherapy reduced the risk of recurrence or death by 50% compared with chemotherapy alone. Such a reduction is considered highly meaningful in the adjuvant setting, where the primary goal is to prevent cancer from returning after initial treatment.
The trial also showed a notable improvement in disease-free survival. At 36 months, 86% of patients treated with Tecentriq plus FOLFOX6 remained disease-free, compared with 76% of patients who received chemotherapy alone.
These findings suggest that the addition of immunotherapy may help a substantial number of patients remain cancer-free for longer periods following surgery.
The study’s results were recently published in the prestigious medical journal The New England Journal of Medicine, further highlighting the scientific importance of the findings.
Safety Profile Consistent with Previous Experience
In addition to demonstrating efficacy, the ATOMIC study evaluated the safety of the combination regimen.
Researchers reported that the safety profile observed in the trial was generally consistent with the known safety characteristics of both Tecentriq and FOLFOX6 chemotherapy.
No unexpected safety concerns were identified, supporting the feasibility of combining immunotherapy with standard chemotherapy in this patient population.
Maintaining a manageable safety profile is particularly important in the adjuvant setting because patients have already undergone surgery and may be free of detectable disease at the time treatment begins. Therapies used in this context must balance effectiveness against the potential for treatment-related side effects.
The consistency of the safety findings provides additional support for the potential use of Tecentriq in earlier-stage disease.
Genentech Highlights Potential New Standard of Care
Levi Garraway, Chief Medical Officer and Head of Global Product Development at Genentech, emphasized the significance of the FDA’s acceptance of the application.
He noted that the milestone brings the company closer to establishing Tecentriq combined with chemotherapy as a potential new standard of care for certain forms of early-stage colon cancer.
Garraway highlighted the ATOMIC results, which demonstrated a substantial reduction in recurrence risk and the potential to help more patients remain cancer-free after surgery.
The findings are particularly important because treatment options specifically tailored to the biology of dMMR/MSI-H tumors have historically been limited in the adjuvant setting.
If approved, the regimen would represent an important example of precision medicine, where treatment strategies are guided by the molecular characteristics of an individual patient’s cancer.
Patient Advocacy Community Welcomes Progress
The development has also been welcomed by patient advocacy organizations focused on colorectal cancer.
Michael Sapienza, Chief Executive Officer of the Colorectal Cancer Alliance, emphasized the ongoing need for improved treatment options in stage III disease.
He noted that approximately one in three patients with stage III colon cancer experiences recurrence within five years despite current treatment approaches. According to Sapienza, the regulatory milestone represents a significant step toward more personalized treatment strategies that take tumor biology into account from the beginning of the treatment journey.
Tailoring therapy based on biomarkers such as dMMR and MSI-H has the potential to improve outcomes while ensuring patients receive treatments most likely to benefit them.
Collaboration Drives Landmark Research
The ATOMIC study reflects a broad collaborative effort involving academic researchers, government organizations, and industry partners.
The trial was sponsored by the National Cancer Institute and conducted through the Alliance for Clinical Trials in Oncology in collaboration with Genentech and the Arbeitsgemeinschaft Internistische Onkologie (AIO) in Germany.
Such partnerships are increasingly important in oncology research because they enable the large-scale studies necessary to evaluate new treatment approaches in specific patient populations.
The success of ATOMIC highlights how cooperation among academic institutions, research networks, government agencies, and pharmaceutical companies can accelerate the development of innovative cancer therapies.
The FDA’s Priority Review of Tecentriq and Tecentriq Hybreza for stage III dMMR/MSI-H colon cancer represents a potentially transformative moment in the treatment of early-stage colorectal cancer.
If approved, the immunotherapy-based regimen could offer a new therapeutic option for patients whose tumors are biologically predisposed to respond to immune checkpoint inhibition. The robust results from the ATOMIC trial suggest that adding Tecentriq to standard chemotherapy may significantly reduce recurrence risk and improve long-term disease-free survival following surgery.
With more than one million new colon cancer diagnoses worldwide each year and a substantial proportion of stage III patients still facing the threat of relapse, advances that improve postoperative outcomes remain urgently needed.
As the FDA reviews the application ahead of its October 2026 decision date, clinicians, patients, and researchers will be watching closely. Approval could mark the beginning of a new era in which biomarker-driven immunotherapy becomes an integral component of curative-intent treatment for early-stage colon cancer, offering renewed hope for thousands of patients at risk of recurrence.
About the ATOMIC study
ATOMIC (A021502, NCT02912559) is a Phase III, randomized, open-label, multicenter study investigating the addition of Tecentriq® (atezolizumab) to FOLFOX6 chemotherapy (a combination of folinic acid, fluorouracil, and oxaliplatin) in patients with stage III colon cancer who have a deficiency in DNA mismatch repair (dMMR). The trial enrolled 712 patients. Participants were randomized 1:1 to receive either FOLFOX6 plus Tecentriq for 12 cycles (six months) followed by Tecentriq monotherapy for 13 cycles (an additional six months), or FOLFOX6 alone for 12 cycles. The primary endpoint is disease-free survival (DFS).
About Tecentriq® (atezolizumab)
Tecentriq is a monoclonal antibody designed to bind with a protein called PD-L1, which is expressed on tumor cells and tumor-infiltrating immune cells, blocking its interactions with both PD-1 and B7.1 receptors. By inhibiting PD-L1, Tecentriq may enable the re-activation of T cells. Tecentriq may also affect normal cells.
Tecentriq has been approved for some of the most aggressive and difficult-to-treat forms of cancer, and is the first PD-(L)1 cancer immunotherapy available in both subcutaneous and intravenous formulations.
